Reasons to invest

OVI 3830 01

Unique production process for salmon oil, preserving quality and and a range of valuable compounds with proven health benefits:

  • Patented enzymatic hydrolysis process uniquely extracting the product from raw material at low temperatures, leaving a range of compounds with health benefits intact
  • Well established, high volume production process in place in Norwegian plants
  • Stable sourcing of high quality raw material from Hofseth International, one of the largest producers of salmon in Norway

Multi-stage long term value creation potential with potential to move into medical treatment

  • Sales mix to progressively move from Feed to high margin Human grade end product
  • Potential to establish JVs and licensing agreements to utilize proprietary Enzymatic Hydrolysis technology & manufacturing to convert low value off-cuts from all marine species to high value products
  • Indications of a range of therapeutic benefits creating potential to establish future collaboration with large cap pharmaceutical corporation
Dr Bomi03

World class R&D with diversified pipeline including research programmes on asthma, COVID 19 and gastro

  • Successful lab work, indicating a link between components in our salmon oil and treating eosinophilic asthma
  • Ongoing fast track study for treatment of COVID-19 patients that are currently asthmatics of former smokers
  • Ongoing pre-clinical studies initiated with primary focus on documenting indications of positive effect gastrointestinal (GI) inflammation
  • Potential for claiming first nutraceutical label for correcting iron deficiency with no iron containing treatment
  • Close relationships with leading research organizations, like Stanford School of Medicine. Clinical trials at leading North American hospitals
Pro Go01

Established cash generative business model based on high value nutrition products

  • Health products like ProGo®, salmon protein hydrolysate containing a mix of bioactive peptides, OmeGo®, fresh, unprocessed fish oil containing all the natural elements of fish oil, and CalGO®, marine bone powder containing all the natural elements of bone – hydroxyapatite, collagen and trace elements
  • Sold on the domestic and global market through in-house distribution and partnerships
  • Cash flow from established business model is funding source for further research
  • Visionary founder and anchor shareholder Roger Hofseth controlling the largest processing capacity of Atlantic salmon as part of a USD 500 million revenue private seafood group.
OMV0283 edit01 cropped

Strong ESG profile, value enhancing waste from the salmon industry

  • Utilizing close to 100% of the off-cuts from the salmon industry
  • Energy efficient production process fuelled by renewable energy